Clinical Scenario #4: Evolving Applications of PARP Inhibitors in Various Cancers
This activity will address the increasing use of PARP inhibitors in the management of patients with solid tumors, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.
Recorded Presentation from the NCCN Pharmacy Updates: The Evolving Landscape of Maintenance Therapy for Ovarian Cancer
This webinar will discuss key concepts in maintenance therapy for ovarian cancer, review clinical efficacy and safety data on potential treatment options and identify and address special considerations for monitoring and patient/caregiver education.
NCCN Guidelines® Insights - Ovarian Cancer, Version 3.2022
These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.
NCCN Pharmacy Updates: The Evolving Landscape of Maintenance Therapy for Ovarian Cancer
This webinar will discuss key concepts in maintenance therapy for ovarian cancer, review clinical efficacy and safety data on potential treatment options and identify and address special considerations for monitoring and patient/caregiver education.
Use of PARP Inhibitors for Ovarian Cancer
The data on PARP inhibitors for treatment of ovarian, primary peritoneal, or fallopian tube cancers has led to substantial changes in the recommendations for molecular testing, maintenance after first-line therapy, recurrence therapy, and maintenance after recurrence therapy.
Navigating Treatment Selection for Patients with Advanced Ovarian Cancer
Multidisciplinary involvement, including nursing and palliative care specialists, is key to providing the best care possible for patients with recurrent/refractory ovarian cancer.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
More than ever before, gynecologic surgeons, oncologists, and pathologists need to work together to assess treatment options for each patient.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
More than ever before, gynecologic surgeons, oncologists, and pathologists need to work together to assess treatment options for each patient.
Selection of Optimal First-Line and Maintenance Therapies in Advanced Ovarian Cancer

Because randomized trial data has shown that many of the options for primary chemotherapy in patients with advanced ovarian cancer have similar outcomes, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Ovarian Cancer includes a large list of regimens – including in

Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers

There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.

Pages

Subscribe to RSS - Ovarian Cancer